142 results on '"Miguel, Jesus San"'
Search Results
2. Health-related quality of life with idecabtagene vicleucel in relapsed and refractory multiple myeloma
3. Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group
4. Isatuximab-pomalidomide-dexamethasone versus pomalidomide-dexamethasone in patients with relapsed and refractory multiple myeloma: final overall survival analysis
5. International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials
6. Highlights of the 11th International Workshop on Waldenstrom's Macroglobulinemia: What we learned, and how it will impact scientific discovery and patient care
7. Quantification of cyclin D1 and D2 proteins in multiple myeloma identifies different expression patterns from those revealed by gene expression profiling
8. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
9. Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma — an IMWG Research Project
10. Outcomes with two different schedules of bortezomib, melphalan, and prednisone (VMP) for previously untreated multiple myeloma: matched pair analysis using long-term follow-up data from the phase 3 VISTA and PETHEMA/GEM05 trials
11. MM-382 iMMagine-3: A Phase 3, Randomized Study to Compare the Efficacy and Safety of Anitocabtagene Autoleucel (Anito-Cel) With Standard of Care in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)
12. Recommendations for acquisition, interpretation and reporting of whole body low dose CT in patients with multiple myeloma and other plasma cell disorders: a report of the IMWG Bone Working Group
13. Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma
14. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial
15. Towards a pan-European burnt scar mapping methodology based on single date medium resolution optical remote sensing data
16. Phase I/II study of weekly PM00104 (Zalypsis®) in patients with relapsed/refractory multiple myeloma
17. Lenalidomide in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma
18. 2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde
19. 2021 European myeloma network review and consensus statement on smoldering multiple myeloma:How to distinguish (and manage) Dr. Jekyll and Mr. Hyde
20. CT-342 Prolonged Hematologic Toxicity After B-Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor (CAR) T-Cell Treatment: From Clinical Data to Ex-Vivo Studies at a Single Center
21. POSTER: CT-342 Prolonged Hematologic Toxicity After B-Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor (CAR) T-Cell Treatment: From Clinical Data to Ex-Vivo Studies at a Single Center
22. IMMUNOPHENOTYPIC ALTERATIONS OF BONE MARROW MYELOID CELL COMPARTMENTS IN MULTIPLE MYELOMA PATIENTS PREDICT FOR MYELODYSPLASIA-ASSOCIATED CYTOGENETIC ALTERATIONS: O44
23. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma
24. Erratum to: Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma
25. Application of Self-Quenched JH Consensus Primers for Real-Time Quantitative PCR of IGH Gene to Minimal Residual Disease Evaluation in Multiple Myeloma
26. International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials
27. International Staging System for Multiple Myeloma
28. Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study
29. Chromatin activation as a unifying principle underlying pathogenic mechanisms in multiple myeloma
30. Phase 3 study (CLARION) of carfilzomib, melphalan, prednisone (KMP) v bortezomib, melphalan, prednisone (VMP) in newly diagnosed multiple myeloma (NDMM)
31. Richter transformation driven by Epstein-Barr virus reactivation during therapy-related immunosuppression in chronic lymphocytic leukaemia
32. A Randomized Comparison of All Transretinoic Acid (ATRA) Followed by Chemotherapy and ATRA Plus Chemotherapy and the Role of Maintenance Therapy in Newly Diagnosed Acute Promyelocytic Leukemia
33. Updated data from a phase II dose finding trial of single agent isatuximab (SAR650984, anti-CD38 mAb) in relapsed/refractory multiple myeloma (RRMM)
34. Adverse event (AE) management in patients (pts) with relapsed and refractory multiple myeloma (RRMM) taking pomalidomide (POM) plus low dose-dexamethasone (LoDEX): A pooled analysis from 3 clinical trials
35. Bone marrow histopathologic patterns and immunologic phenotype in B-cell chronic lymphocytic leukaemia
36. Pembrolizumab (MK-3475) in combination with lenalidomide and low-dose dexamethasone for relapsed/refractory multiple myeloma (RRMM): KEYNOTE-023
37. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma
38. MyelomA Genetics International Consortium
39. Abstract C66: Role of mTORC1 and mTORC2 in multiple myeloma and their targeting with CC214.
40. Future Directions of Next-Generation Novel Therapies, Combination Approaches, and the Development of Personalized Medicine in Myeloma
41. International Myeloma Working Group Consensus Statement Regarding the Current Status of Allogeneic Stem-Cell Transplantation for Multiple Myeloma
42. Survival and Years of Life Lost in Different Age Cohorts of Patients With Multiple Myeloma
43. The Effect of Paraprotein Heavy Chain and Free Light Chain Types on the Efficacy of Pegylated Liposomal Doxorubicin + Bortezomib Versus Bortezomib Alone in Patients with Relapsed/Refractory Multiple Myeloma
44. The Effect of Bone Marrow Involvement on the Efficacy of Pegylated Liposomal Doxorubicin + Bortezomib Vs Bortezomib Alone in Patients with Relapsed/Refractory Multiple Myeloma
45. Effect of Disease Stage and Time Since Diagnosis on Time to Progression for Pegylated Liposomal Doxorubicin + Bortezomib vs Bortezomib Alone in Relapsed or Refractory Multiple Myeloma.
46. The Prolonged Time to Progression with Pegylated Liposomal Doxorubicin + Bortezomib Versus Bortezomib Alone in Relapsed or Refractory Multiple Myeloma Is Unaffected by Extent of Prior Therapy or Previous Anthracycline Exposure.
47. The Effect of In Vivo T-Cell Depletion with Alemtuzumab on Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation for Chronic Lymphocytic Leukemia.
48. Tandem Autologous Transplant Versus Reduced Intensity Conditioned Allogeneic Transplant (Allo-RIC) as Second Intensification in Chemosensitive Patients with Multiple Myeloma (MM) Not Achieving Complete Remission (CR) or Near-CR with a First Autologous Transplant. Results from a Spanish PETHEMA/GEM Study.
49. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial
50. Influence of GST Gene Polimorphisms in the Develovement of Liver Sinusoidal Obstructive Syndrome in Patients with Multiple Myeloma Undergoing Hematopoietic Stem Cell Transplantation.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.